Skip to main content

Table 2 Summary of inputs used in the base-case model

From: Cost-effectiveness analysis of combining traditional Chinese medicine in the treatment of hypertension: compound Apocynum tablets combined with Nifedipine sustained-release tablets vs Nifedipine sustained-release tablets alone

Items Base Case Range Source
Baseline age 67.5 60 ~ 75 MF Ju [29]
Transition probability
 Alive without stroke/MI  stroke
  Nifedipine 0.460% 0.0041 ~ 0.0051
0.0009 ~ 0.0011
[29,30,31]
  Compound Apocynum+ Nifedipine Levamlodipine 0.102% 0.0009 ~ 0.0011 [29,30,31]
 Alive without stroke/MI  stroke
  Nifedipine 0.199% 0.0018 ~ 0.0022 [29,30,31]
  Compound Apocynum+ Nifedipine Levamlodipine 0.193% 0.0017 ~ 0.0021 [29,30,31]
Stroke →Stroke 41.7%(5 year) 0.3753 ~ 0.4587 [32]
Post-stroke →Death 25.6%(4 year) 0.2304 ~ 0.2816 [33]
Stroke →Death 13.03%(5 year) 0.1172 ~ 0.1433 [33]
MI → MI 12.50% 0.1125 ~ 0.1375 [34]
Post-MI → Death 6.10% 0.0549 ~ 0.0671 [35]
MI → Death 9.70% 0.0873 ~ 0.1067 [34]
Utility
 Alive without stroke 0.98 0.882 ~ 1 [36]
 Stroke 0.5 0.45 ~ 0.55 [37]
 MI 0.70 0.63 ~ 0.77 [37]
 Post-stroke 0.63 0.567 ~ 0.693 [37]
 Post-MI 0.8 0.72 ~ 0.88 [37]
Cost (USD/per year)
 Nifedipine drug costs 16.31 14.68 ~ 17.95 [38]
 Compound Apocynum+Nifedipine drug costs ii 102.42 92.18 ~ 112.66 [38]
MI (in hospital) 2538.01 2284.26 ~ 2791.87 [39]
Stroke (in hospital) 1843.86 1659.56 ~ 2028.35 [39]
Post-stroke 1692.15 1522.93 ~ 1861.36 [40]
Post-MI 20,141.84 1837.66 ~ 2246.03 [40]